Literature DB >> 17005475

Total remission of thymus carcinoma after treatment with intravenous immunoglobulin.

Manuel Murie-Fernández1, Alfonso Gurpide, Susana de la Cruz, Purificación de Castro.   

Abstract

We report the case of a 42 year-old woman with myasthenia gravis associated with a malignant thymoma. Despite surgery, chemotherapy and radiotherapy, the thymoma showed soft tissues, pleural and mediastinic progression. Unexpectedly, a complete remission of the thymoma was confirmed by FDG-PET after four cycles of immunoglobulins, administered as treatment for a myasthenic crisis. To our knowledge this is the first case report of complete remission of a malignant thymoma with immunoglobulin therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17005475     DOI： 10.1007/s12094-006-0043-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  6 in total

Review 1.  Thymoma: state of the art.

Authors:  C R Thomas; C D Wright; P J Loehrer
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

2.  Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease.

Authors:  V Hoffacker; A Schultz; J J Tiesinga; R Gold; B Schalke; W Nix; R Kiefer; H K Müller-Hermelink; A Marx
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis.

Authors:  C Buckley; D Douek; J Newsom-Davis; A Vincent; N Willcox
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

Review 4.  Successful treatment of thymoma-associated pure red cell aplasia with intravenous immunoglobulins.

Authors:  C Larroche; L Mouthon; N Casadevall; G Le Roux; P Casassus; L Guillevin
Journal:  Eur J Haematol       Date:  2000-07       Impact factor: 2.997

Review 5.  Malignant thymoma: current status of classification and multimodality treatment.

Authors:  I G H Schmidt-Wolf; J K Rockstroh; H Schüller; A Hirner; C Grohe; H K Müller-Hermelink; D Huhn
Journal:  Ann Hematol       Date:  2003-02-11       Impact factor: 3.673

Review 6.  Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature.

Authors:  Y Levy; A Afek; Y Sherer; Y Bar-Dayan; R Shibi; J Kopolovic; Y Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  1998-10       Impact factor: 5.532
  6 in total
  3 in total

Review 1.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

2.  Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice.

Authors:  Qian Xu; Zaiping Zhang; Zhiming Chen; Biying Zhang; Chanyuan Zhao; Yimin Zhang; Conghui Zhao; Xiaodong Deng; Yao Zhou; Yanyun Wu; Jiang Gu
Journal:  Cancer Manag Res       Date:  2019-03-07       Impact factor: 3.989

3.  Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells.

Authors:  Bogdana Kovalchuk; Anna S Berghoff; Matthia A Karreman; Katharina Frey; Manuel Piechutta; Manuel Fischer; Julia Grosch; Sabine Heiland; Michael O Breckwoldt; Frank Hilberg; Wolfgang Wick; Frank Winkler
Journal:  Clin Exp Metastasis       Date:  2020-09-12       Impact factor: 5.150
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.